[{"abstract": "The company said Colleen Goggins, 56, who has been overseeing one of the company\u2019s three major divisions, would retire in March.", "web_url": "https://www.nytimes.com/2010/09/17/business/17tylenol.html", "snippet": "The company said Colleen Goggins, 56, who has been overseeing one of the company\u2019s three major divisions, would retire in March.", "lead_paragraph": "A longtime senior executive at Johnson & Johnson in charge of the consumer products division is leaving the company early next year, signaling a shake-up after a troubling series of recalls, including of children\u2019s Tylenol, tarnished the company\u2019s reputation in the last year. ", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2010/09/17/business/Tylenol/Tylenol-jumbo.jpg", "height": 1024, "width": 738, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2010/09/17/business/Tylenol/Tylenol-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2010/09/17/business/Tylenol/Tylenol-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "Chief of Unit With Recalls to Exit J.&J.", "kicker": null, "content_kicker": null, "print_headline": "Chief of Unit With Recalls To Exit J.&J.", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Recalls and Bans of Products", "rank": 1, "major": "N"}, {"name": "subject", "value": "Suspensions, Dismissals and Resignations", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Tylenol (Drug)", "rank": 4, "major": "N"}], "pub_date": "2010-09-17T01:24:50+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Natasha Singer and Reed Abelson", "person": [{"firstname": "Natasha", "middlename": null, "lastname": "Singer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Reed", "middlename": null, "lastname": "Abelson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/ef52036b-6b01-554e-bf12-6c59480e49d7", "word_count": 694, "uri": "nyt://article/ef52036b-6b01-554e-bf12-6c59480e49d7"}, {"abstract": "Hedge fund managers who closed their firms are opening new funds, and in some cases promising to make previous investors whole before taking performance fees.", "web_url": "https://dealbook.nytimes.com/2010/09/17/hedge-fund-managers-set-up-for-next-acts/", "snippet": "Hedge fund managers who closed their firms are opening new funds, and in some cases promising to make previous investors whole before taking performance fees.", "lead_paragraph": "James J. Pallotta, a legend of the hedge fund industry, is calling a do-over, Julie Creswell writes in The New York Times.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Hedge Fund Managers Set Up for Next Acts", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Pallotta, James J", "rank": 1, "major": "N"}], "pub_date": "2010-09-17T06:03:44+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/f0973667-02eb-5480-aed0-3e2936838f5d", "word_count": 179, "uri": "nyt://article/f0973667-02eb-5480-aed0-3e2936838f5d"}, {"abstract": "Johnson & Johnson, the U.S. health products company, said Friday that it was in advanced talks to offer for the 82 percent of Crucell, a Dutch biopharmaceutical firm, that it does not already own, in what would be a 1.75 billion euro deal.", "web_url": "https://dealbook.nytimes.com/2010/09/17/johnson-johnson-bids-2-3-billion-for-crucell/", "snippet": "Johnson & Johnson, the U.S. health products company, said Friday that it was in advanced talks to offer for the 82 percent of Crucell, a Dutch biopharmaceutical firm, that it does not already own, in what would be a 1.75 billion euro deal.", "lead_paragraph": "Johnson & Johnson, the American health products company, said Friday that it was in advanced talks to bid for the 82 percent of Crucell, a Dutch biopharmaceutical firm, that it does not already own, in what would be a 1.75 billion euro ($2.3 billion) deal.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Johnson & Johnson Mulling $2.3 Billion Crucell Bid", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2010-09-17T09:54:39+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chris V. Nicholson", "person": [{"firstname": "Chris", "middlename": "V.", "lastname": "Nicholson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/a72f448a-7365-5c1e-9af7-259c10f6abb3", "word_count": 296, "uri": "nyt://article/a72f448a-7365-5c1e-9af7-259c10f6abb3"}]